Characterisation of SARDS-ILD

  • Research type

    Research Study

  • Full title

    Characterisation of the clinical features and outcomes of patients with interstitial lung disease associated with systemic autoimmune rheumatic diseases (SARDS-ILD)

  • IRAS ID

    343794

  • Contact name

    Shaney Barratt

  • Contact email

    shaney.barratt@nbt.nhs.uk

  • Sponsor organisation

    North Bristol NHS Trust

  • Duration of Study in the UK

    1 years, 2 months, 5 days

  • Research summary

    Interstitial lung disease is a term describing a large number of different diseases all of which can cause inflammation and irreversible scar tissue formation in the lungs. Some interstitial lung diseases may occur as a result of an underlying autoimmune disease (when the immune system damages host tissues). These often respond well to treatment with medications that suppress the immune system.
    However, the most common form of interstitial lung disease (idiopathic pulmonary fibrosis – which occurs without an underlying disease process), may suffer unintended harm if treated with these medications (Raghu, 2012).
    It is therefore important to ensure that patients with interstitial lung diseases as a result of an underlying autoimmune disease are recognised early and offered appropriate treatment. This is with the intention of avoiding any progression of the disease which can lead to irreversible lung damage.
    Additionally, due to their rarity, relatively little is known about interstitial lung diseases secondary to autoimmune diseases and to what extent chest scan features, lung tissue samples, blood test results and other features of the disease may associate with the severity natural history and responsiveness to treatment of the disease.
    This work aims to define and characterise cases of interstitial lung disease secondary to underlying systemic autoimmune rheumatic diseases (SARDS) and compare clinical, radiological, blood test features and responses to treatment to those with idiopathic pulmonary fibrosis.

  • REC name

    South East Scotland REC 01

  • REC reference

    24/SS/0096

  • Date of REC Opinion

    11 Dec 2024

  • REC opinion

    Favourable Opinion